(Q34614976)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

review article

1 reference

title

Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Jesus Castilla

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

author name string

Javier García-Samaniego

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

José María Miró

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Jorge Del Romero

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Miguel Bruguera

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Juan Ignacio Esteban

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Juan Gonźlez

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Eduardo Lissen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Alberto Moreno

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Santiago Moreno

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Ricardo Moreno-Otero

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Enrique Ortega

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Carmen Quereda

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Manuel Rodríguez

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

José María Sánchez-Tapias

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Spanish Hepatitis-HIV Consensus Panel

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

publication date

1 March 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

99-114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Hepatitis C and HIV infection: biological, clinical, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Risks of chronicity following acute hepatitis B virus infection: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Correlates of hepatitis C virus infections among injection drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Hepatitis C virus infection in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Epidemiology of hepatitis C: geographic differences and temporal trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Significance of HCV RIBA-2 indeterminate results in high-risk individuals: assessment by a new third-generation RIBA assay and PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Natural history of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Management of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Lactic acidosis associated with stavudine administration: a report of five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. The Hepatitis/HIV Spanish Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Hepatitis B virus infection in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Clinical aspects of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Reappearance of Hepatitis B Virus in Immune Patients Infected with the Human Immunodeficiency Virus Type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Transplantation in HIV+ patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Outcome of orthotopic liver transplantation in patients with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FH2CF-3KNA-Q3Y9-C3G1

10.1310/H2CF-3KNA-Q3Y9-C3G1

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11976988%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference